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assessment of circulating 
Protein signatures for Kidney 
Transplantation in Pediatric 
recipients
Tara K. Sigdel* and Minnie M. Sarwal
University of California, San Francisco, San Francisco, CA, United States
Identification and use of non-invasive biomarkers for kidney transplantation monitoring 
is an unmet need. A total of 121 biobanked sera collected from 111 unique kidney 
transplant (KT) patients (children and adolescent) and 10 age-matched healthy normal 
controls were used to profile serum proteins using semi-quantitative proteomics. The 
proteomics data were analyzed to identify panels of serum proteins that were specific 
to various transplant injuries, which included acute rejection (AR), BK virus nephropathy 
(BKVN), and chronic allograft nephropathy (CAN). Gene expression data from matching 
peripheral blood mononuclear cells were interrogated to investigate the association 
between soluble serum proteins and altered gene expression of corresponding genes in 
different injury phenotypes. Analysis of the proteomics data identified from different patient 
phenotypes, with criteria of false discovery rate <0.05 and at least twofold changes in 
either direction, resulted in a list of 10 proteins that distinguished KT injury from no injury. 
Similar analyses to identify proteins specific to chronic injury, acute injury, and AR after 
kidney transplantation identified 22, 6, and 10 proteins, respectively. Elastic-Net logistic 
regression method was applied on the 137 serum proteins to classify different transplant 
injuries. This algorithm has identified panels of 10 serum proteins specific for AR, BKVN, 
and CAN with classification rates 93, 93, and 95%, respectively. The identified proteins 
could prove to be potential surrogate biomarkers for routine monitoring of the injury 
status of pediatric KT patients.
Keywords: kidney transplantation, serum proteins, transplant injury, acute rejection, protein biomarkers
inTrODUcTiOn
Organ transplantation is the treatment of choice for patients with organ failure (1). The number 
of individuals in the waiting list outnumbers the organs that are available for transplantation (2). 
Recent advancements in immunosuppressive therapy and surgical techniques have contributed 
in lowering early acute rejection (AR) events; however, long-term outcome of the transplanted 
organs is still not satisfactory (3). Since transplanted organs continuously endure injuries that are 
immune and non-immune related, it is important to reduce such injuries. A better understanding 
Abbreviations: AR, acute rejection; CAN, chronic allograft nephropathy; BKVN, BK virus nephropathy; CNIT, calcineurin 
inhibitor toxicity; STA, stable graft function.
Table 1 | Demographic data of kidney transplant patients used in the study.
Phenotype ar sTa can cniT bKVn
Number of patients 27 25 25 20 14
Steroid-free/steroid-based 14/13 13/12 11/13 13/7 6/8
Recipient gender (M/F) 18/9 17/8 14/11 13/7 5/7
Recipient race: 1 = White,  
2 = Asian,  
3 = African American,  
4 = Native American and Pacific Islanders, 
5 = Mixed and others
1 = 12 1 = 11 1 = 12 1 = 9 1 = 6
2 = 6 2 = 7 2 = 7 2 = 5 2 = 2
3 = 3 3 = 2 3 = 2 3 = 3 3 = 2
4 = 1 4 = 1 4 = 2 4 = 0 4 = 0
5 = 5 5 = 4 5 = 5 5 = 3 5 = 4
Recipient agea (years) 12 ± 5 (14; 10–19) 16 ± 3 (16; 10–19) 12 ± 6 (9; 8–18) 11 ± 6 (11; 3–17) 11 ± 5 (9; 8–18)
Living/deceased 16/11 7/18 16/9 12/8 8/6
Donor gender (M/F) 13/14 14/11 14/11 10/10 9/5
Donor agea 28 ± 8 (29; 17–37) 28 ± 10 (27; 14–47) 24 ± 8 (25; 16–31) 28 ± 10 (28; 17–37) 24 ± 8 (25; 16–31)
Average post-Txp time (months) 7 ± 5 6 ± 3 8 ± 4 8 ± 3 8 ± 5
AR, acute rejection; STA, stable graft function; CAN, chronic allograft nephropathy; CNIT, calcineurin inhibitor toxicity; BKVN, BK virus nephropathy.
aAge in years: mean ± SD (median; range).
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of the detailed mechanism of transplant injury would help in 
the proper management of transplanted organs for long-term 
survival (4).
Recent developments in high-throughput assays such as gene 
microarrays and mass spectrometry-based proteomics have 
proven to be useful in profiling gene transcripts (mRNA) and 
proteins, and this global-scale molecular profiling has helped in 
a better understanding of homeostasis of organ failure (5–9). By 
analyzing carefully selected samples using advanced statistics, 
gene microarrays, and mass spectrometry-based proteomics, we 
can provide a global picture of gene expression and correspond-
ing protein levels specific to disease conditions (6–8, 10–15). 
We and other groups have previously reported genes, proteins, 
and antibodies that are associated with different transplant 
injuries, including AR (5, 10, 12, 16, 17). Our recent studies have 
demonstrated that mechanisms of graft rejection are common 
across different solid organs (10, 18, 19). These observations 
have suggested a strong signal for T cell activation, T cell recep-
tor engagement, and interferon gamma- and STAT1-regulated 
pathways driven through various chemokines (10). Additional 
molecular data from carefully selected patient cohorts would 
provide additional information to our current understanding 
and provide potential biomarkers for detection of transplant 
injuries.
The objective of this study was to identify signatures of serum 
proteins that are associated with KT injury in pediatric patient 
population. To meet the objective, we used a unique set of 121 
serum samples from pediatric patients with kidney transplan-
tation and performed mass spectrometry-based proteomics, 
followed by statistical and bioinformatic analyses to identify pro-
teins that are associated with different kinds of transplant injuries 
in kidney. In addition, we also interrogated gene expression data 
from matching peripheral blood mononuclear cells (PBMCs) 
to investigate if there existed any correlation between the level 
of serum proteins and the gene expression of corresponding 
proteins in matching PBMCs.
MaTerials anD MeThODs
Patient samples
Serum samples were collected from 111 unique pediatric kidney 
transplant (KT) patients from Lucile Packard Children’s Hospital, 
Stanford University. Sera from 10 age-matched healthy normal 
controls were also included in the study as a non-transplant 
control. Each sample was matched with a biopsy collected at the 
time of serum collection. The study included 27 AR, 20 calcineu-
rin inhibitor toxicity (CNIT), 25 chronic allograft nephropathy 
(CAN), 14 BK virus nephropathy (BKVN), and 25 normal graft 
function without significant injury [stable graft function (STA)] 
samples. All the study samples were collected from pediatric 
and young adult recipients transplanted between years 2000 and 
2011 at Lucile Packard Children’s Hospital of Stanford University. 
The study was approved by the ethics committees of Stanford 
University Medical School and UCSF Medical Center. All adult 
patients and parents/guardians of non-adult patients provided 
written informed consent to participate in the research, in full 
adherence to the Declaration of Helsinki. The clinical and research 
activities being reported are consistent with the Principles of the 
Declaration of Istanbul as outlined in the Declaration of Istanbul 
on Organ Trafficking and Transplant Tourism. A summary of 
demographic information of KT patients and a summary of study 
samples and analysis scheme are provided in Table 1 and Figure 1. 
All the kidney biopsies were blindly analyzed by a Stanford 
University pathologist and were graded by the Banff classification 
(20–22) for AR, and intragraft C4d stains were performed (23, 24) 
to assess for acute humoral rejection (25, 26). Transplant “injury” 
was defined as a >20% increase in serum creatinine from its previ-
ous steady-state baseline value and an associated biopsy that was 
classified as AR, CAN, CNIT, BKVN, or STA. AR was defined at 
minimum, as per Banff schema, as a tubulitis score ≥1 accompa-
nied with an interstitial inflammation score ≥1 with both C4d and 
DSA negative. For this study, we included only T-cell-mediated 
AR. Antibody-mediated rejection cases were excluded from the 
FigUre 1 | Study sample classification scheme. STA, stable kidney graft with normal function; AR, acute rejection; CAN, chronic allograft nephropathy; CNIT, 
calcineurin inhibitor toxicity; BKVN, BK virus nephropathy.
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study. CAN was defined at minimum as a tubular atrophy score 
≥1 accompanied by an interstitial fibrosis score ≥1. The histo-
logical lesions of chronic CAN were extensively identified, and a 
semi-quantitative score for CAN was applied to each biopsy, based 
on standardized definitions from the Banff (2), chronic allograft 
damage index (3), and chronic CNIT (19) scores. BKVN was 
defined as positivity of polyomavirus PCR in peripheral blood, 
together with a positive SV40 stain in the concomitant renal allo-
graft biopsy. Normal (STA) allografts were defined by an absence 
of significant injury pathology as defined by Banff schema.
serum sample collection and storage
Blood samples (4.5 mL) were collected into a 5 mL red top tube 
and incubated at room temperature for 30 min until the clot was 
formed. The sample was then centrifuged at 2,000 × g for 5 min 
using a swinging bucket rotor. The upper layer of serum was then 
transferred to another cryotube and was stored at −80°C until 
use.
Mass spectrometry
Serum samples were depleted of the 20 most abundant serum 
proteins by ProteoPrep20 Plasma Immunodepletion Kit 
(Sigma-Aldrich, St. Louis, MO, USA, Cat. PROT20). The elu-
ate from each sample was subsequently subjected to trypsin 
digestion with a standard trypsin digestion protocol. Tryptic 
 peptides were reconstituted in a buffer containing 0.2% formic 
acid, 2% acetonitrile, and 97.8% water prior to mass spectrometry. 
The high-performance liquid chromatography utilized was an 
Eksigent nano2D (Eksigent) with a self-packed 150 μM ID C18, 
15 cm column. The electrospray source was a Michrom Advance 
operated at 600  nL/min on an LTQ Orbitrap Velos (Thermo 
Fisher). Data acquisition was performed in a data-dependent 
manner in which the top 12 (Velos) most intense-charged peptide 
ions were selected for MS/MS fragmentation of charge state 2+ 
and 3+. Data were subsequently extracted with msconvert script 
into an mzXML format prior to Sorcerer (SAGE-N) analysis with 
the Sequest algorithm. The IPI human database was searched 
using a 50 ppm mass window on the precursor ion. We allowed 
for the static modification of propionamide on cysteine and 
variable modifications of methionine oxidation and lysine acety-
lation. All searches were compiled and displayed in a Scaffold 
(Proteome Software Inc., Portland, OR, USA) interface, which 
listed the identified proteins with cumulative spectral counts for 
each protein.
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gene expression analysis
Gene expression analysis was performed for gene expression 
aberrations on a subset of whole blood collected at the same time 
from the study subjects for the proteomics study. This analysis 
included blood samples collected from 11 AR, 11 STA, 9 CAN, 
9 BKVN, and 9 CNIT patients. Blood was collected in 2.5 mL 
PAXgene™ Blood RNA Tubes (PreAnalytiX, Qiagen, Valencia, 
CA, USA). Total RNA was extracted, and cDNA synthesis was 
done using a previously published protocol (27). Synthesized 
cDNA was then hybridized onto GeneChip Human Genome 
U133 Plus 2.0 Arrays (Affymetrix Inc., Santa Clara, CA, USA). 
The arrays were washed and scanned as recommended by the 
Ovation Biotin RNA Amplification and Labeling System User 
Guide (version 1.0) (NuGEN Inc., San Carlos, CA, USA). The 
data were analyzed using AltAnalyze software (28). Genes were 
considered to have differentially expressed by an empirical Bayes 
t test, p value <0.05, and fold change 1.5.
Data analysis
Data analysis was done in three steps. First, we performed ANOVA 
to identify injury-specific serum proteins in KT injury. In this step, 
mass spectrometric data were analyzed with settings that included 
the false discovery rate (FDR) for protein identifications 0.1% 
based on target decoy analysis using Sequest® and the FDR at the 
unique peptide level 0.2%. The spectral counts for the identical IPI 
numbers were summed. After filtering for proteins that were not 
consistently identified in different samples, the identified proteins 
were used for further analysis. In the first step, the data were quan-
tile-normalized and used for ANOVA analysis. Phenotype-specific 
proteins were identified with ANOVA with the criteria FDR <0.05 
and at least twofold change in either direction. Principal compo-
nent analysis (PCA) plots and heatmaps were generated using 
Partek Genomics Suite (Partek Inc., St. Louis, MO, USA).
In the second step, we used penalized logistic regression to 
identify proteins that could serve as potential surrogate bio-
markers for different KT injuries. This approach provides not 
only accurate estimation for the regression coefficients but also 
probability estimation for each patient (29, 30). We used the 
regularization paths for generalized linear models via Coordinate 
Descent for the estimations (30). The logistic equation used is:
 
log ( )
( )
-odds=ln pi
pi
β β β β
x
x
x x xK K1 0 1 1 2 2−





 = + + + +
 
where π(x) =  P(x) (case) and x1, …, xK are the expressions of 
K proteins for observations x. The Elastic-Net fits this model by 
adding a mixed penalty term to the likelihood
 
l x y xi
T
i
n
k k
k
K
k
K
( | ) log( exp( )) ( ) | |β β λ α β α β= − + − − + −
= ==
∑ ∑∑1 1
1
2
11



.
 
We fitted 100 Elastic-Net logistic regression models to the 
137 proteins using bootstrapped samples maintaining the use of 
~75% samples in the training set and ~25% samples in the test set 
to classify between transplant samples and non-transplant sam-
ples with different transplant injury status. For each bootstrap, a 
nested cross-validation loop estimated the best value according to 
the deviance. The parameter of the Elastic-Net was fixed at 0.95, 
the value recommended by Friedman et al. (30). The mean test 
classification rate was 96%. We counted the number of times each 
protein was selected by the Elastic-Net over the 100 bootstraps. 
For each of the bootstrap samples, the Elastic-Net fit a subset of 
the 137 proteins with non-zero coefficients. For each protein, we 
counted the number of bootstrap samples for which the protein 
had non-zero coefficients. After running the 100 bootstrapped 
models, we selected the K proteins with the greatest number 
of non-zero coefficients. Classification with the reduced set of 
K proteins: in order to have an unbiased estimation of the pre-
dictive performance (classification rate, sensitivity, specificity, 
PPV, and NPV), we ran another set of 100 bootstrap Elastic-Net 
classifications with nested cross-validation for λ, this time using 
only the set of K proteins selected in step 1. Finally, in the third 
step, we fitted the selected models to the whole dataset to give the 
regression coefficients.
resUlTs
The objective of this study was to identify KT injury-specific 
proteins. By the proteomics analysis of serum proteins, we 
identified 137 proteins across all the samples with the criteria of 
(i) minimum two peptides per protein for a positive identification 
and (ii) 0.1% FDR for protein and 0.2% FDR for peptide identi-
fication Sequest® (31). An enrichment analysis for the biological 
association of the 137 proteins listed complement and coagula-
tion cascade (p =  4.79E−38) and peptidase inhibitor activity 
(p = 1.02E−13) as the top associations of the proteins identified.
serum Proteins specific to Different 
injury subtypes
To identify KT injury status, ANOVA was performed on prot-
eomics data with the criteria of FDR <0.05 and at least twofold 
change in either direction for significance. (i) Injury vs no injury: 
for this, the samples were classified in to injury (AR, CAN, CNIT, 
BKVN) and no injury (STA and HC). Ten differentially expressed 
unique proteins were identified specific to kidney injury after 
transplantation (Table  2). These 10 proteins were significantly 
associated with a complement activation pathway (FDR = 0.006). 
(ii) Chronic injury-specific serum protein markers: the contrast 
between CAN/CNIT (Chronic) and AR/BK/STA (non-chronic) 
identified 22 differentially expressed proteins listed in Table  2. 
These proteins are associated with positive regulation of cho-
lesterol esterification (FDR  =  5.26E−10), plasma lipoprotein 
particle remodeling (FDR = 5.64E−08), regulation of response 
to wounding (FDR = 5.64E−08), and regulation of inflammatory 
response (FDR = 1.02E−07). (iii) Acute injury-specific proteins: 
we identified 6 differentially expressed proteins between patients 
with acute injury (AR and BKVN) and those with chronic injury 
(CAN and CNIT) or STA (Table 2). These proteins are associated 
with blood coagulation pathways. (iv) Identification of AR with 
10 proteins: 10 differentially expressed proteins were identified 
between patients with AR and those without AR (CAN, CNIT, 
BKVN, and STA) (Table  2). These 10 proteins are associated 
with defense response (FDR = 0.006), positive regulation of cho-
lesterol esterification (FDR = 0.005), and positive regulation of 
triglyceride catabolic process (FDR = 0.006). PCA on the proteins 
Table 2 | List of serum proteins specific to kidney transplant injury.
Transplant vs no transplant (acute rejection (ar), chronic allograft 
nephropathy, calcineurin inhibitor toxicity, bK virus nephropathy, stable 
graft function vs hc)
s. no. Protein name p-Value (injury 
vs no injury)
ratio (injury vs no 
injury)
1 Complement factor properdin 
(CFP)
8.85E−06 8.47E−03
2 CXCL7 2.73E−05 6.01E−04
3 Afamin (AFM) 6.27E−05 2.73E−09
4 IGHG4 immunoglobulin heavy 
constant gamma 4
3.89E−04 1.03E−03
5 Clusterin 1.19E−03 7.62E−04
6 Apolipoprotein A-II (APOA2) 1.51E−03 1.31E−03
7 Uncharacterized protein 3.76E−03 9.37E−04
8 Butyrylcholinesterase (BCHE) 2.91E−04 9.45E+01
9 Lumican (LUM) 3.09E−04 2.02E+03
10 C8G complement component 
8, gamma polypeptide
2.63E−03 4.06E+01
chronic injury
Protein name p-Value 
(chronic injury 
vs non-chronic)
ratio (chronic 
injury vs 
non-chronic)
1 Apolipoprotein A-IV (APOA4) 5.19E−16 5.16E−14
2 Fibronectin 1 (FN1) 5.90E−05 9.40E−09
3 CFP 4.40E−04 1.12E−01
4 AFM 2.26E−03 1.59E−04
5 PROS1 protein S 2.84E−03 1.91E−01
6 AGT angiotensinogen 2.94E−03 2.51E−02
7 Complement factor B (CFB) 4.62E−03 2.39E−05
8 C5 complement component 5 4.82E−03 6.99E−04
9 Apolipoprotein E 5.62E−03 7.46E−03
10 LUM 8.42E−03 2.54E+01
11 Attractin (ATRN) 8.22E−13 2.88E+02
12 alpha-2-HS-glycoprotein 
(AHSG)
1.57E−10 1.61E+11
13 Histidine rich glycoprotein 
(HRG)
3.89E−07 7.89E+02
14 BCHE 3.43E−05 2.23E+01
15 IGHV4-31 1.09E−04 3.90E+06
16 CPN2, Carboxypeptidase N 1.67E−03 1.24E+01
17 A1BG alpha-1-B glycoprotein 2.69E−03 4.14E+04
18 IGHM 2.73E−03 2.52E+03
19 Apolipoprotein C-I 2.84E−03 1.81E+01
20 Apolipoprotein A-I (APOA1) 2.88E−03 4.23E+22
21 SELL selectin L 2.96E−03 4.91E+00
22 LGALS3BP lectin galactoside-
binding, etc.
3.63E−03 1.11E+01
acute injury
Protein name p-Value (acute 
vs non)
ratio (acute vs 
non)
1 AHSG 5.59E−14 2.06E−15
2 ATRN 4.84E−11 4.26E−03
3 IGHV4-31 5.94E−04 6.09E−07
4 IGHG2 1.16E−03 5.24E−05
5 APOA4 2.83E−11 1.11E+11
6 FN1 2.17E−03 2.84E+06
ar
Protein name p-Value (ar vs 
no ar)
ratio (ar vs no 
ar)
1 AHSG 1.68E−08 3.71E−11
2 APOA4 1.10E−06 5.49E+07
3 ATRN 2.09E−05 3.54E−02
4 CFB 6.53E−04 1.15E+06
5 SERPINA3 7.04E−04 2.07E+16
6 APOA1 1.25E−03 2.65E−27
7 IGHG2 1.35E−03 5.53E−05
8 C5 complement component 5 1.70E−03 6.50E+03
9 IGHA1 immunoglobulin heavy 
constant alpha 1
2.29E−03 1.36E+02
10 HRG 2.47E−03 1.62E−02
(Continued)
Table 2 | Continued
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identified for injury, chronic injury, acute injury, and AR dem-
onstrated a good separation of the phenotypes (Figures 2A–D).
identification of serum Protein Panel  
for Different KT injuries
To identify transplant injury-specific panels, we fitted 100 
Elastic-Net logistic regression models to the 137 proteins using 
bootstrapped samples maintaining the use of ~75% samples 
in the training set and ~25% samples in the test set to classify 
transplant samples and non-transplant samples with different 
transplant injury status. (i) KT-specific panel: analysis of healthy 
normal control (HC) vs transplant samples identified 10 proteins 
(APOB, GPLD1, PLG, 66 kDa protein (IPI00941961.1), CP, ALB, 
apolipoprotein A-II (APOA2), IGHG3, ORM2, and SAA4) on the 
whole dataset as proteins specific to transplantation. The box-and-
whisker plot in Figure 3A shows separation of projection score 
for different phenotypes. The ROC analysis was performed for 
the classification potential, which resulted in AUC of one by the 
model consisting of 10 proteins. The interception and regression 
coefficients are shown in Table 3. (ii) Injury-specific protein panel: 
next, we sought to identify a panel of proteins that separate serum 
samples with kidney injury from those with well-functioning kid-
neys. A panel of 10 proteins was identified, which classified injury 
(AR, CAN, CNIT, BKVN) (n = 86) vs no injury (STA and HC) 
(n = 35). The mean classification rate, sensitivity, specificity, PPV, 
and NPV were 0.92. 0.96, 0.84, 0.93, and 0.91, respectively. The 
interception and regression coefficients are shown in Table 3. (iii) 
Acute injury protein panel: next, we identified 10 proteins that were 
specific to acute transplant injury (AR and BKVN) compared with 
no acute injury (CAN, CNIT, HC, and STA). The mean classifica-
tion rate for the 10 protein panel was 98% [CI 95% = (95.8, 100)], 
sensitivity = 0.95, specificity = 0.98, PPV = 0.95, NPV = 0.98. The 
interception and regression coefficients are shown in Table 3. (iv) 
Biomarker protein panel for AR: the analysis that compared protein 
signal from AR samples against all non-AR samples identified 10 
proteins to classify AR (n = 27) vs others (CAN, CNIT, BKVN, 
STA, and HC) (n = 94). The mean classification rate was 0.91. The 
sensitivity, specificity, PPV, and NPV were 0.74, 0.96, 0.83, and 
0.93, respectively. The interception and regression coefficients are 
shown in Table 3. Figure 3C shows the separation of projection 
FigUre 2 | Serum proteins specific to different transplant injury phenotypes were identified. (a) A principal component analysis (PCA) plot generated by 10 serum 
proteins that separate samples collected from patients with kidney injury from samples collected from patients with no kidney injury. (b) A PCA plot generated by 22 
serum proteins that separate chronic injury samples from samples collected from patients with no chronic injury in their kidney. (c) A PCA plot generated by six 
serum proteins that separate serum samples from the patients with acute injury from the samples collected from patients with no acute injury. (D) A PCA plot 
generated by 10 serum proteins that separate serum samples from the patients with acute rejection (AR) from the samples collected from patients with no AR.
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score for AR with other phenotypes. (v) Biomarker proteins for 
BKVN: a panel of 10 proteins was identified that was able to 
classify BKVN (n = 14) vs others (n = 107) with a mean classifica-
tion rate 0.93. The sensitivity, specificity, PPV, and NPV were 0.65, 
0.96, 0.69, and 0.95, respectively. The interception and regression 
coefficients are shown in Table 3. Figure 3 shows the separation of 
projection score for AR with other phenotypes. (vi) Serum protein 
biomarkers to distinguish CAN vs CNIT: a panel of 10 proteins 
was identified that classified CAN (n =  25) vs CNIT (n =  20). 
The mean classification rate was 0.95. The sensitivity, specificity, 
PPV, and NPV were 0.96, 0.94, 0.96, and 0.95, respectively. The 
interception and regression coefficients are shown in Table 3.
gene expression analysis of Whole blood 
from a subset of serum samples Used in 
Proteomics analysis
A subset of PBMCs with matching serum samples from the 
same collection date for each patient was analyzed. A total 
of 9,665 genes were significantly different in whole blood 
by ANOVA (p < 0.05). Among these, only 39 proteins (gene 
products) were identified in our serum proteomics data. 
With the significance criteria of an empirical Bayes t test p 
value <0.05 and a fold change of two vs stable graft (STA), 
a total of 626 upregulated genes were identified, which 
enriched for the biological system process (FDR =  0.0004). 
In addition, there were 7,316 downregulated genes enriched 
in AR, which are associated with cellular macromolecule 
metabolic process (FDR =  5.1E−14) and primary metabolic 
process (FDR = 2.1E−13). There were 12 upregulated and 713 
downregulated genes in CAN. CAN-associated genes were 
highly enriched in immune system process (FDR = 7.4E−9) 
and response to stress (FDR =  2.4E−6). Blood from BKVN 
patients demonstrated 141 upregulated and 1,321 down-
regulated genes in BKVN, which were enriched in anatomical 
structure morphogenesis (FDR = 4.2E−05) and transcription 
regulatory region DNA binding (FDR =  0.005). There were 
seven upregulated and 290 downregulated genes associated 
FigUre 3 | 10 protein biomarker models for different kidney injury phenotypes. (a) A box-and-whisker plot for 10 protein panel specific for transplantation when 
compared to no transplant healthy normal controls (HC). (b) A box-and-whisker plot for 10 protein panel specific for kidney injury due to kidney transplantation 
when compared to well-functioning kidneys after transplantation [stable graft function (STA)] and healthy normal controls (HC). (c) A box-and-whisker plot for 10 
protein panel specific for acute rejection (AR) when compared to no AR phenotypes. (D) A box-and-whisker plot for 10 protein panel specific for BK virus 
nephropathy (BKVN) when compared to serum from patients with absence of BKVN.
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with CNIT. These CNIT-associated genes were enriched in 
viral transcription process (FDR =  0.003). Even though we 
were not expecting to see correlation between serum protein 
level and gene expression in the whole blood, we noticed that 
some serum protein levels had aligned with corresponding 
gene expression levels in the PBMCs. Among those genes, 
complement factor properdin (CFP), attractin (ATRN), serum 
IgA (IGHG2 – gene), and clusterin (CLU) levels were down-
regulated in acute injury, including AR (both gene expression 
and protein level).
DiscUssiOn
Despite the fact that there is an urgent need to improve long-term 
survival of transplanted organs, the organs succumb to immune- 
and non-immune-related causes (32). Sequencing of human 
genome and subsequent development of “omic” platforms have 
led us to investigate the biology of transplant rejection and failure 
(15, 17, 33). The data presented in recently published reports have 
helped our understanding in immune-related processes (3–7). 
Similar studies to identify serum proteins in transplant injuries 
have been published, but they suffer from either small sample 
size (34) or a lack of diversity of injuries to really understand 
the perturbations of those proteins (35). In addition, rejection 
is a heterogenous biological process, and it has been accepted 
that the possibility that a single gene or protein could serve as 
a surrogate biomarker or represent the multitude of biological 
events that occur concurrently during transplant injury (36) is 
unlikely. The semi-quantitative proteomics strategy used in this 
study and the penalized logistic regression to identify potential 
biomarker protein panels for different KT injury phenotypes is 
a novel approach that we used in the context of biomarker dis-
covery of serum proteins in kidney transplantation. The method 
has provided accurate estimates for the regression coefficients 
and probability estimates for each transplant injury phenotype in 
pediatric KT recipients (29, 30).
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There are several important findings in this report. First, we 
identified proteins associated with different transplant injuries. 
A broad analysis to identify transplant injury-associated proteins 
listed proteins such as CFP, which is known as a positive regulator 
of complement activation (37), and CLU, which is known to help 
with the clearance of cellular debris and apoptosis (38). Six out 
of eight proteins identified were associated with complement 
activation and alternative pathways. Complement and coagula-
tion cascade-related proteins such as complement component 
(C5), complement factor B (CFB), and Protein S alpha (PROS1) 
were associated with chronic injury. Involvement of the comple-
ment system in transplant rejection and chronic injury has been 
reported (39, 40). Association of complement and coagulation 
cascade-related proteins is relevant as a response to immune 
system and vascular injury to the organ. A set of immune 
regulatory proteins namely alpha-2-HS-glycoprotein (AHSG), 
apolipoprotein A-IV (APOA4), ATRN, IgG, and fibronectin 1 
(FN1) were associated with acute injury. Fibronectin is known 
to participate in cell adhesion, growth, migration, and differen-
tiation (41). Soluble FN is expressed in hepatocytes (42) and is 
produced as a response to vascular injury (43). Our observation 
of a decreased level of serum fibronectin (FN) in chronic injury 
and increased level of FN in acute injury, which includes AR 
and BKVN, is interesting as its protein level in in the blood and 
expression in the rat kidney has been studied in the context of 
transplant rejection with no clear association (44–47). Molecules 
involved in the regulation of defense and inflammatory response 
are namely AHSG/fetuin-A, APOA4, ATRN, CFB, SERPINA3, 
apolipoprotein A-I, IgG, complement component 5 (C5), immu-
noglobulin heavy constant alpha 1 (IgA), and histidine-rich 
glycoprotein. The elevation of these proteins in the blood during 
an AR episode is attributed to the response to the acute inflam-
mation due to rejection.
Second, using a penalized logistic regression panel, we have 
identified panels of 10 proteins as a surrogate biomarker panel 
for different transplant injuries. After several efforts in biomarker 
discovery for AR and other transplant injuries, it has now become 
evident that finding a single gene or protein as a biomarker is 
almost impossible. Biomarker discovery and validation is an 
arduous task and takes a long-term study and many validation 
steps. Even though we started off with identifying the panel of 
potential biomarker proteins, and validation of biomarker panels 
was not the scope of this study, we utilized data generated in this 
to identify potential biomarker panels for transplant injuries and 
validated them using ~25% of the study samples. To this end, 
using our penalized logistic regression model, we have identified 
10 protein panels for transplant, transplant injury, AR, acute 
injury that included AR and BKVN, and a panel that differenti-
ates CAN from CNIT. The sensitivity, specificity, PPV, and NPV 
are listed for different models, which show some promise for 
these proteins to serve as biomarkers. We acknowledge the small 
sample size and therefore consequently our results could suffer 
from overfitting. Validation of this will require use of more pro-
spectively collected samples in a clinical trial setting on a larger 
cohort of patient samples.
The third important finding of this study is that profiling of 
serum proteins and profiling of transcriptome from whole blood 
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provided complementary information about the perturbations in 
the blood in case of other injuries and allowed us to compare 
complementary information about molecular pathways that were 
obtained from serum proteomics and gene expression of the blood 
cells. Even though the overlap in between the serum proteins 
(n = 137) to gene expression data (n = ~20,000) was minimal, 
this is our effort to understand the molecular perturbations in 
different tissue types. This approach is important as analyzing 
different tissue types will help build a complete picture of biologi-
cal events that occur during an immune or non-immune insult 
to the transplanted kidney.
In conclusion, using a high-throughput semi-quantitative mass 
spectrometry-based proteomics approach with serum samples 
from pediatric KT patients; we have identified proteins associ-
ated with different transplant injuries in kidney transplantation. 
We acknowledge some limitations of this study, including that its 
conclusions are based on discovery data and lack independent 
validation. We acknowledge that the use of a strategy that used 
depletion of high abundant proteins, including the possibility that 
we depleted any potential biomarker that was albumin-bound. 
Every discovery study like this should be followed up with a 
larger validation study using an independent cohort of samples 
for proteins and genes as a surrogate biomarker for KT injury. 
With this promising result in hand, we are planning studies that 
will include validation of identified proteins and genes in a set of 
prospectively collected samples. This longitudinal sample-set will 
also determine whether the increased or decreased level of the 
serum proteins correlates with injury status over time.
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